Please assess the completion status of the following clinical trial:

Trial Title: Glimepiride vs Metformin as Monotherapy in Pediatric Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
INCLUSION CRITERIA:~1. Subjects who had type 2 diabetes treated with diet and exercise only for at least 2 weeks prior to randomization, or who were previously or currently treated with an oral agent and had not responded to diet, exercise, and oral therapy for at least 3 months (documented by an HbA1c \>7.5%).~2. Subjects who completed glimepiride pharmacokinetic Study HOE 490/4045 at preselected sites within 3 weeks prior to the screening period were also permitted to enroll.~3. Subjects were required to be negative for islet cell antigen (ICA) and glutamic acid decarboxylase (GAD) autoantibodies and to have a C-peptide level at 90 minutes of ≥ 1.5 ng/mL. The HbA1c was required to be \>7.1% at screening and \<12.0% on the day of randomization.~EXCLUSION CRITERIA:~Subjects meeting any of the following criteria were not to be included in the study:~1. A history of an acute metabolic complication such as diabetic ketoacidosis within 3 months before screening~2. On insulin therapy, or had received insulin for \>6 weeks, 3 months prior to randomization~3. On weight-reduction medication~4. Known hypersensitivity to biguanides, sulfonamides, or insulin~5. Pregnant or lactating females~6. Clinically significant renal (serum creatinine level \>1.0 mg/dL) or hepatic disease (alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\] \>2.5 times the upper limits of normal \[ULN\])~7. GI disorders that may interfere with the absorption of the study drugs~8. Chronic use of medications known to affect glucose levels such as intermittent use of systemic corticosteroids or large dose of inhaled steroids~9. Clinically significant laboratory abnormality on screening laboratory tests or any medical condition that in the opinion of the investigator would affect the outcome of the study~10. History of drug or alcohol abuse~11. Treatment with any investigational product in the last 3 months before study entry~12. History of noncompliance with regard to follow-up medical care~13. Any disease or condition that in the opinion of the investigator and/or sponsor may interfere with completion of the study

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).